About Diaxonhit
Diaxonhit is a company based in Paris (France) founded in 1997. Diaxonhit has raised $65.46 million across 7 funding rounds from investors including Danske Bank, BNP Paribas and HHS. Diaxonhit has completed 1 acquisition, including InGen. Diaxonhit operates in a competitive market with competitors including Abcam, Inscripta, Stem Cell Technologies, GenScript and OncoDNA, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$65.46 M (USD)
in 7 rounds
-
Latest Funding Round
$2.4 M (USD), Grant
Jun 05, 2012
-
Investors
Danske Bank
& 8 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Diaxonhit
Diaxonhit has successfully raised a total of $65.46M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $2.4 million completed in June 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Diaxonhit
Diaxonhit has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Danske Bank, BNP Paribas and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences sector focused early stage VC firm investing primarily in Europe
|
Locked | Locked | Locked | |
|
Early stage VC firm investing in the US and Korea
|
Locked | Locked | Locked | |
|
Diversified asset management, corporate advisory, and private equity firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Diaxonhit
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Diaxonhit
Diaxonhit has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include InGen.
Investment portfolio details for Diaxonhit
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
IVD products for Infectious and autoimmune diseases
|
Locked | Locked | 1993 | Locked |
Complete acquisition details for Diaxonhit
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Diaxonhit
Detailed financials for Diaxonhit
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Diaxonhit Comparisons
Peer comparison for Diaxonhit
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Diaxonhit
Diaxonhit operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Inscripta, Stem Cell Technologies, GenScript and OncoDNA, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biological reagents and antibodies are developed for life science research.
|
|
| Locked | Locked | Locked |
Speech recognition solutions are provided by Inscripta for healthcare professionals.
|
|
| Locked | Locked | Locked |
Developer of cell culture media and ancillary reagents for life science research
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Genomic and theranostic services for oncology precision medicine are delivered.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
Detailed competitors of Diaxonhit
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Diaxonhit
Complete news archive for Diaxonhit
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Diaxonhit
Diaxonhit was founded in 1997 and raised its 1st funding round 3 years after it was founded.
Diaxonhit is headquartered in Paris, France.
Diaxonhit is a funded company, having raised a total of $65.46M across 7 funding rounds to date.
The Diaxonhit group is a fully integrated in-vitro diagnostics company with expertise ranging from discovery to commercialization of specialty diagnostic products. The company was a result of the acquisition of InGen BioSciences by Exonhit. Diaxonhit owns a broadened and diversified portfolio of proprietary diagnostic products in three specialty areas : transplantation, infectious diseases and cancer diagnosis. The group is currently marketing two proprietary products, TQS (Tetanus Quick Stick) for the evaluation of patients immune status against tetanus, and BJI Inoplex for the diagnosis of bone joint prosthetic infections. The group also commercializes AlloMap, a molecular test for the surveillance of heart-transplant patients, under an exclusive licence for Europe. Additionally, Diaxonhit develops other diagnostic products using its molecular biology platform, including Dx15, a molecular diagnostic test for thyroid cancer. Diaxonhits commercial affiliate, InGen, is currently the leading independent distributor of in vitro diagnostics in the French market. It markets specialty diagnostic tests to public and private clinical laboratories. InGen is the market leader in France for distribution of HLAs tests (Human Leukocyte Antigen) that assess the compatibility between donors and recipients for organ and bone marrow transplants, and enable surveillance of rejection after transplantation. InGen also distributes tests for European and American partners in the field of infectious diseases, auto-immunity and quality control products.
Diaxonhit's top competitors include Abcam, Sino Biological and OncoDNA.
Diaxonhit has made 1 acquisition, including InGen.
Diaxonhit has 9 investors. Key investors include Danske Bank, BNP Paribas, HHS, Edmond de Rothschild, and Idinvest Partners.